Advanced search

Show items per page
Elements: 7
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines Phillips, Andrew N; Bansi-Matharu, Loveleen; Venter, Francois; Havlir, Diane; ... Bertagnolio, Silvia 2020
add to browser selection
More evidence for dolutegravir as first-line ART for all Estill, Janne Anton Markus; Bertisch, Barbara 2020
add to browser selection
The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS. Kelly, Sherrie L; Martin-Hughes, Rowan; Stuart, Robyn M; Yap, Xiao F; ... Wilson, David P 2018
add to browser selection
Anti-inflammatory therapy in well controlled HIV infection Tarr, Philip E; Calmy, Alexandra 2018
add to browser selection
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP) Ciaffi, Laura; Koulla-Shiro, Sinata; Sawadogo, Adrien Bruno; Ndour, Cheik Tidiane; ... Calmy, Alexandra 2017
add to browser selection
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis Kanters, Steve; Socias, Maria Eugenia; Paton, Nicholas I; Vitoria, Marco; ... Mills, Edward J 2017
add to browser selection
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; ... Calmy, Alexandra 2017